![]() |
產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號(hào) | CS10694 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
CAS編號(hào) | |
抗體名 | Anti-Phospho-PAR4 (Thr163) |
克隆性 | |
靶點(diǎn) | 詳見說明書 |
適應(yīng)物種 | 詳見說明書 |
形態(tài) | 詳見說明書 |
宿主 | 詳見說明書 |
亞型 | IgG |
標(biāo)識(shí)物 | 詳見說明書 |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated Synthesised phosphopeptide derived from human PAR4 around the phosphorylation site of Thr163 |
產(chǎn)品訂購(gòu)信息:
英文名稱 Anti-Phospho-PAR4 (Thr163)
中文名稱 磷酸化蛋白酶活化受體4抗體規(guī)格
別 名 PAR 4; Par4 induced by effectors of apoptosis; PAWR; PRKC Apoptosis WT1 Regulator; PRKC apoptosis WT1 regulator protein; Prostate apoptosis response 4 protein; Prostate apoptosis response protein 4; Prostate apoptosis response protein PAR 4; Proteinase-Activated Receptor 4; Transcriptional repressor Par-4-like protein PAWR; TRANSCRIPTIONAL REPRESSOR PAR4; WT1 Interacting Protein; protease-activated receptor 4; 2310001G03Rik.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat
產(chǎn)品類型 一抗 磷酸化抗體
研究領(lǐng)域 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子
蛋白分子量 predicted molecular weight: 44kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human PAR4 around the phosphorylation site of Thr163
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
磷酸化蛋白酶活化受體4抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 PAR4 is a member of a unique family of GPCRs, the proteinase-activated receptors (PARs), that are activated by proteolytic cleavage of the N-terminal domain of the receptor to reveal a tethered ligand. The PAR family consists of 4 receptors; PAR1 and PAR3 are activated by thrombin, and PAR2 and PAR4 are activated by several serine proteases (Macfarlane et al., 2001). PAR4 is expressed along with PAR1 on human platelets, and each plays an important role in thrombin-induced platelet aggregation (Holinstat et al., 2006). However, platelets from mice express PAR4 but not PAR1, and platelets from mice lacking PAR4 fail to aggregate in response to thrombin (Sambrano et al., 2001). Mice lacking PAR4 are protected from mesenteric arteriole thrombosis, indicating that PAR4 is a potential target for treatment of thrombosis in humans.
蛋白酶活化受體-4(細(xì)胞凋亡反應(yīng)蛋白4)是蛋白酶活化受體PARs (protease-activated receptors , PARs)的成員之一,PAR4在激活、滅活、脫敏、復(fù)敏、及其與信號(hào)轉(zhuǎn)導(dǎo)途徑的關(guān)系,尤其是與疾病的關(guān)系正倍受關(guān)注。
PAR4具有廣泛的生物學(xué)效應(yīng),最終影響細(xì)胞的形態(tài)的改變、分泌蛋白和整合蛋白的活化、代謝反應(yīng)、轉(zhuǎn)錄過程和細(xì)胞運(yùn)動(dòng),由此參與細(xì)胞的信號(hào)轉(zhuǎn)導(dǎo)作用。
Anti-Phospho-CHK2 (Thr68)/FITC 熒光素標(biāo)記磷酸化細(xì)胞周期檢測(cè)點(diǎn)激酶2抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Anti-ILK-1/FITC 熒光素標(biāo)記整合素連接激酶-1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh CD105/Endoglin CD105抗體 規(guī)格 0.1ml
Integrin a7(integrin alpha 7) 整合素α7抗原 0.5mg
IER2 英文名稱: 即刻早期應(yīng)答基因2蛋白抗體 0.2ml
Rhesus antibody Rh SPRR3/Cornifin B 角質(zhì)蛋白β抗體 規(guī)格 0.2ml
Anti-ILK-1/FITC 熒光素標(biāo)記整合素連接激酶-1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Anti-JAK1/FITC 熒光素標(biāo)記蛋白質(zhì)酪氨酸激酶JAK-1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Anti-phospho-SHC (Tyr317)/FITC 熒光素標(biāo)記磷酸化SH2結(jié)構(gòu)域轉(zhuǎn)化蛋白1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh Amphetamine(2A3F6) 單克隆抗體() 規(guī)格 0.1ml
Rabbit Anti-mouse IgG-Fc/Alexa Fluor 647 Alexa Fluor 647標(biāo)記的兔抗小鼠IgG-Fc 0.1ml
GOLGA3 英文名稱: 高爾基體膜相關(guān)蛋白抗體 0.1ml
Rhesus antibody Rh Rabbit Anti-horse IgG/Cy7 Cy7標(biāo)記的兔抗馬IgG 規(guī)格 0.1ml
Anti-phospho-SHC (Tyr317)/FITC 熒光素標(biāo)記磷酸化SH2結(jié)構(gòu)域轉(zhuǎn)化蛋白1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Casp-9 ELISA Kit 大鼠胱天蛋白酶9Multi-class antibodies規(guī)格: 48T
Anti-TRP2 酪氨酸酶相關(guān)蛋白2抗體Multi-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh Gibberellins 磺酸/β-氨基乙磺酸抗體 規(guī)格 0.1ml
OPGL(Mouse Osteoprotegerin Ligand) ELISA KIT 小鼠骨保護(hù)素配體 96T
Phospho-NuMA (Ser395) 英文名稱: 磷酸化核有絲分裂器NuMA蛋白抗體 0.1ml
AMPD1 英文名稱: 腺苷單磷酸脫酶1抗體 0.2ml
Anti-TRP2 酪氨酸酶相關(guān)蛋白2抗體Multi-class antibodies規(guī)格: 0.2ml
CL-0136L6(大鼠成肌細(xì)胞)5×106cells/瓶×2
GPT Others Rat 大鼠 GPT1 / GPT 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對(duì)照)
人氣管平滑肌細(xì)胞裂解物HTSMCL
HPAC細(xì)胞,人*癌細(xì)胞 人上皮細(xì)胞,16HBE細(xì)胞 皮膚肥大細(xì)胞Many types of cells包裝:5 × 105次方(1ml)
兔眼Tenon's囊成纖維細(xì)胞;RYTF
TGFBR2 Others Human 人 TGFβR2 / TGFR2 人細(xì)胞裂解液 (陽性對(duì)照)
CL-0135L1210(小鼠細(xì)胞)5×106cells/瓶×2
CD14 Others Human 人 CD14 人細(xì)胞裂解液 (陽性對(duì)照)
小鼠小腸內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL
Pig MSC豬骨髓間質(zhì)干細(xì)胞 Pig MSC of porcine bone marrow mesenchymal stem cells DMEM低糖+10% FBS+glutamin
IL6 Protein Rat 重組大鼠 IL6 / Ierleukin-6 蛋白
RM1(大鼠肌肉成纖維樣細(xì)胞) 5×106cells/瓶×2 PC-12未分化(大鼠腎上腺嗜鉻細(xì)胞瘤)
磷酸化蛋白酶活化受體4抗體規(guī)格 KLRC1 Others Cynomolgus 食蟹猴 NKG2A / NKG2 / CD159A / KLRC1 人細(xì)胞裂解液 (陽性對(duì)照)
人晶狀體上皮細(xì)胞總RNAHLEpiC NA
貓星形腦膠質(zhì)細(xì)胞;PG-4(S+L-)
PC-3細(xì)胞,人*癌細(xì)胞 人表皮癌細(xì)胞,A-431細(xì)胞 小鼠胚胎成纖維細(xì)胞;BALB/C 3T3
Hs 746T(人細(xì)胞) 5×106cells/瓶×2
Gibco 17100017 Collagenase Type I 1g
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn):
1. 磷酸化蛋白酶活化受體4抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件;
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等;
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用;
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定:
1)磷酸化蛋白酶活化受體4抗體規(guī)格 抗體的效價(jià)鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。